Liposome Assisted Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others); Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Others)
Report Code: TIPRE00013462
| No. of Pages: 150
| Category: Medical Device
| Status: Upcoming
Liposomes are a novel drug delivery system (NDDS), formed by spontaneous dispersion of phospholipids in water. Liposomes are aqueous bilayer vesicular structures of phospholipids. They are microscopic vesicles in which an aqueous volume is completely surrounded by a membrane composed of lipid bilayers. This novel drug delivery system aims to deliver the drug at targeted site and at a rate directed by the requirement of the body over the period of treatment. Some of the drugs are formulated as liposomes in order to improve their therapeutic index such as doxorubicin, paclitaxel, amphotericin and others.
Major factor driving the growth of the global Liposome Assisted Drug Delivery market is the increased research in liposome technology and its role in modulating drug delivery systems in human body and advantages offered by liposomal drug delivery such as reduced toxicities and enhanced efficacy. Growing interests across the healthcare continuum across the world has resulted into increasing research and development activities in an ever-evolving Liposome Assisted Drug Delivery landscape and technological advancements in novel drug delivery systems. Furthermore, growing adoption of Liposome Assisted Drug Delivery in order to particular diseased cells such as malignant cells will continue to propel the overall market growth. However, High costs of production for Liposome Assisted Drug Delivery and Short half-life Low solubility in body of liposome are some of the factors restraining the market growth.
The Liposome Assisted Drug Delivery market analysis to 2028 is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Liposome Assisted Drug Delivery market with detailed market segmentation by product and applications. The Liposome Assisted Drug Delivery market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Liposome Assisted Drug Delivery market and offers key trends and opportunities in the market.
The Liposome Assisted Drug Delivery market is segmented on the basis of Product and Application. Based on Product, the market is segmented as Liposomal Doxorubicin, Liposomal Amphotericin B, Liposomal Paclitaxel, Others. On the basis of application, the market is segmented as Fungal Infection Therapy, Cancer & Tumor Therapy, Others.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Liposome Assisted Drug Delivery market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Liposome Assisted Drug Delivery market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Liposome Assisted Drug Delivery market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Liposome Assisted Drug Delivery market in these regions.
Get more information on this report :
The report covers key developments in the Liposome Assisted Drug Delivery market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Liposome Assisted Drug Delivery market are anticipated to have lucrative growth opportunities in the future with the rising demand for Liposome Assisted Drug Delivery in the global market. Below mentioned is the list of few companies engaged in the Liposome Assisted Drug Delivery market.
The report also includes the profiles of key players in Liposome Assisted Drug Delivery market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Johnson & Johnson
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Gilead Sciences
4. Johnson & Johnson
5. Luye Pharma
6. Sun Pharmaceutical
8. Sigma-Tau Group
9. Teva Pharmaceutical
10. Ipsen (Onivyde)